Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. Conventional treatment options have limited efficacy because most cases are in the advanced stage at the time of diagnosis. In recent years, gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has shown its good antitumor activities in treating NSCLC in a number of studies. This paper reviews its role in the targeted treatment of NSCLC in Chinese patients.
CITATION STYLE
Li, M. J., He, Q., Li, M., Luo, F., & Guan, Y. S. (2016, March 9). Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. OncoTargets and Therapy. Dove Medical Press Ltd. https://doi.org/10.2147/OTT.S80635
Mendeley helps you to discover research relevant for your work.